Silo Pharma Advances Canadian Patent for PTSD Therapy
SARASOTA, Fla., August 18, 2026 Silo Pharma, Inc. announced that the Canadian Intellectual Property Office (CIPO) has issued a...
Silo Pharma
Advertisement
Silo Pharma Gains European Patent for SPC-15 PTSD Therapy
SARASOTA, Fla., August 10, 2026 Silo Pharma, Inc. announced that the European Patent Office (EPO) has granted a patent...
Silo Pharma Advances AI Through AMD Program
SARASOTA, Fla., July 14, 2026 Silo Pharma announced that its wholly owned subsidiary, QwikAgents, has been accepted into AMD’s...
Silo Pharma Advances SPC-15 PTSD Program Toward FDA Meeting
SARASOTA, Fla., June 29, 2026 Silo Pharma announced that it has initiated a drug-device robustness study for SPC-15, its...
Silo Pharma Moves SPC-15 Into Phase 1 Clinical Development
Sarasota, Florida | December 30, 2025 — Silo Pharma, Inc. has taken a key step toward early-stage clinical development...
Advertisement
